Latest Articles

With the increasing complexities of current IND programs, it is critical to work with regulatory agencies to seek input early in the process. read more

In large pharma, a staggering 40 to 50 percent of expert pharmacovigilance time is still consumed by tasks far removed from active, scientific PV - such as the mechanics of scheduling reports, tracking down contributors, and managing documents. read more